Regenxbio IncNASDAQ:RGNX
- LAST PRICE14.3500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots12.7000/ 20
- Ask / Lots16.1700/ 1
- Open / Previous Close14.4800 / 14.3500
- Day Range
- 52 Week Range
- Volume424,738
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 2668 | 14.34 |
| 09:36 ET | 100 | 14.36 |
| 09:38 ET | 400 | 14.54 |
| 09:39 ET | 100 | 14.61 |
| 09:41 ET | 100 | 14.63 |
| 09:43 ET | 2800 | 14.72 |
| 09:45 ET | 500 | 14.7 |
| 09:48 ET | 600 | 14.755 |
| 09:50 ET | 508 | 14.7 |
| 09:52 ET | 1853 | 14.745 |
| 09:54 ET | 300 | 14.73 |
| 09:56 ET | 700 | 14.75 |
| 09:57 ET | 401 | 14.71 |
| 09:59 ET | 1200 | 14.705 |
| 10:01 ET | 1303 | 14.715 |
| 10:03 ET | 500 | 14.73 |
| 10:06 ET | 500 | 14.72 |
| 10:08 ET | 340 | 14.71 |
| 10:10 ET | 300 | 14.71 |
| 10:12 ET | 3100 | 14.65 |
| 10:14 ET | 800 | 14.6 |
| 10:15 ET | 600 | 14.645 |
| 10:17 ET | 600 | 14.74 |
| 10:19 ET | 200 | 14.71 |
| 10:21 ET | 600 | 14.74 |
| 10:24 ET | 2010 | 14.715 |
| 10:26 ET | 700 | 14.77 |
| 10:28 ET | 2948 | 14.78 |
| 10:30 ET | 450 | 14.76 |
| 10:32 ET | 808 | 14.73 |
| 10:33 ET | 100 | 14.81 |
| 10:35 ET | 300 | 14.805 |
| 10:37 ET | 1200 | 14.71 |
| 10:39 ET | 711 | 14.76 |
| 10:42 ET | 1000 | 14.7 |
| 10:48 ET | 600 | 14.65 |
| 10:51 ET | 100 | 14.6 |
| 10:53 ET | 100 | 14.6 |
| 10:55 ET | 784 | 14.6 |
| 10:57 ET | 300 | 14.61 |
| 11:00 ET | 100 | 14.61 |
| 11:02 ET | 1222 | 14.6 |
| 11:04 ET | 100 | 14.58 |
| 11:06 ET | 300 | 14.59 |
| 11:08 ET | 400 | 14.59 |
| 11:09 ET | 815 | 14.605 |
| 11:11 ET | 200 | 14.63 |
| 11:13 ET | 100 | 14.63 |
| 11:15 ET | 1300 | 14.58 |
| 11:22 ET | 3700 | 14.52 |
| 11:26 ET | 4999 | 14.47 |
| 11:36 ET | 100 | 14.5 |
| 11:38 ET | 100 | 14.49 |
| 11:40 ET | 100 | 14.5 |
| 11:44 ET | 217 | 14.4807 |
| 11:45 ET | 1203 | 14.52 |
| 11:49 ET | 3969 | 14.53 |
| 11:54 ET | 200 | 14.48 |
| 12:02 ET | 200 | 14.465 |
| 12:05 ET | 1904 | 14.475 |
| 12:07 ET | 258 | 14.4701 |
| 12:09 ET | 200 | 14.48 |
| 12:14 ET | 2423 | 14.44 |
| 12:23 ET | 600 | 14.44 |
| 12:25 ET | 620 | 14.43 |
| 12:27 ET | 100 | 14.46 |
| 12:30 ET | 307 | 14.47 |
| 12:32 ET | 200 | 14.485 |
| 12:34 ET | 750 | 14.48 |
| 12:36 ET | 200 | 14.48 |
| 12:38 ET | 100 | 14.475 |
| 12:39 ET | 400 | 14.47 |
| 12:41 ET | 100 | 14.475 |
| 12:43 ET | 1678 | 14.47 |
| 12:48 ET | 100 | 14.46 |
| 12:54 ET | 100 | 14.5 |
| 12:56 ET | 402 | 14.5 |
| 12:57 ET | 100 | 14.5 |
| 12:59 ET | 100 | 14.52 |
| 01:01 ET | 100 | 14.51 |
| 01:03 ET | 776 | 14.5 |
| 01:06 ET | 700 | 14.48 |
| 01:12 ET | 600 | 14.53 |
| 01:14 ET | 1000 | 14.48 |
| 01:15 ET | 440 | 14.46 |
| 01:21 ET | 400 | 14.455 |
| 01:24 ET | 1700 | 14.43 |
| 01:26 ET | 1000 | 14.33 |
| 01:30 ET | 100 | 14.37 |
| 01:32 ET | 300 | 14.35 |
| 01:33 ET | 100 | 14.35 |
| 01:35 ET | 200 | 14.34 |
| 01:42 ET | 755 | 14.345 |
| 01:44 ET | 100 | 14.33 |
| 01:46 ET | 768 | 14.33 |
| 01:48 ET | 200 | 14.34 |
| 01:51 ET | 200 | 14.36 |
| 01:53 ET | 600 | 14.38 |
| 01:57 ET | 435 | 14.37 |
| 02:00 ET | 100 | 14.36 |
| 02:02 ET | 140 | 14.3721 |
| 02:04 ET | 1008 | 14.355 |
| 02:06 ET | 300 | 14.31 |
| 02:08 ET | 225 | 14.32 |
| 02:09 ET | 700 | 14.34 |
| 02:13 ET | 100 | 14.38 |
| 02:15 ET | 200 | 14.36 |
| 02:18 ET | 200 | 14.38 |
| 02:20 ET | 100 | 14.4 |
| 02:22 ET | 1358 | 14.4 |
| 02:24 ET | 400 | 14.39 |
| 02:26 ET | 801 | 14.38 |
| 02:31 ET | 648 | 14.32 |
| 02:33 ET | 400 | 14.3405 |
| 02:40 ET | 100 | 14.355 |
| 02:44 ET | 300 | 14.36 |
| 02:47 ET | 200 | 14.36 |
| 02:54 ET | 2177 | 14.27 |
| 02:56 ET | 200 | 14.2875 |
| 02:58 ET | 100 | 14.285 |
| 03:02 ET | 2204 | 14.27 |
| 03:03 ET | 802 | 14.26 |
| 03:05 ET | 300 | 14.27 |
| 03:09 ET | 411 | 14.27 |
| 03:14 ET | 100 | 14.275 |
| 03:16 ET | 400 | 14.27 |
| 03:18 ET | 200 | 14.26 |
| 03:20 ET | 2461 | 14.22 |
| 03:21 ET | 200 | 14.2275 |
| 03:23 ET | 708 | 14.25 |
| 03:27 ET | 300 | 14.28 |
| 03:30 ET | 1854 | 14.26 |
| 03:32 ET | 1574 | 14.25 |
| 03:34 ET | 100 | 14.26 |
| 03:36 ET | 1000 | 14.27 |
| 03:38 ET | 2479 | 14.34 |
| 03:39 ET | 600 | 14.33 |
| 03:41 ET | 1473 | 14.3525 |
| 03:43 ET | 3477 | 14.4 |
| 03:45 ET | 1100 | 14.4 |
| 03:48 ET | 2308 | 14.35 |
| 03:50 ET | 1400 | 14.33 |
| 03:52 ET | 3712 | 14.4 |
| 03:54 ET | 4794 | 14.4 |
| 03:56 ET | 5161 | 14.39 |
| 03:57 ET | 4370 | 14.4 |
| 03:59 ET | 22458 | 14.35 |
May 15, 2024
DJ REGENXBIO Is Maintained at Buy by HC Wainwright & Co., from 11:41AM ET on Wednesday May 15, 2024 by Dow Jones
11:41AM ET on Wednesday May 15, 2024 by Dow Jones
May 10, 2024
REGENXBIO to Participate in Upcoming Investor Conferences, from 7:05AM ET on Friday May 10, 2024 by Dow Jones
7:05AM ET on Friday May 10, 2024 by Dow Jones
May 8, 2024
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones
4:05PM ET on Wednesday May 08, 2024 by Dow Jones*DJ REGENXBIO 1Q Loss/Shr $1.38 >RGNX, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones
4:05PM ET on Wednesday May 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 706.8M | -2.4x | --- |
SAGE Therapeutics Inc | 692.1M | -1.3x | --- |
WAVE Life Sciences Ltd | 755.6M | -12.0x | --- |
Zymeworks Inc | 596.0M | -4.7x | --- |
Y-mAbs Therapeutics Inc | 527.0M | -24.4x | --- |
Urogen Pharma Ltd | 489.6M | -3.9x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Allan Fox
- President, Chief Executive Officer, Director
- Kenneth Mills
- Chief Financial Officer, Executive Vice President
- Vittal Vasista
- Chief Operating Officer, Executive Vice President
- Curran Simpson
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $706.8M |
|---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.34 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | 8.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
